Synthesis, Characterization, and Assessment of Anti-Cancer Potential of ZnO Nanoparticles in an In Vitro Model of Breast Cancer
Advanced innovations for combating variants of aggressive breast cancer and overcoming drug resistance are desired. In cancer treatment, ZnO nanoparticles (NPs) have the capacity to specifically and compellingly activate apoptosis of cancer cells. There is also a pressing need to develop innovative anti-cancer therapeutics, and recent research suggests that ZnO nanoparticles hold great potential. Here, the in vitro chemical effectiveness of ZnO NPs has been tested. Zinc oxide (ZnO) nanoparticles were synthesized using Citrullus colocynthis (L.) Schrad by green methods approach. The generated ZnO was observed to have a hexagonal wurtzite crystal arrangement. The generated nanomaterials were characterized by transmission electron microscopy (TEM), scanning electron microscopy (SEM), UV-visible spectroscopy. The crystallinity of ZnO was reported to be in the range 50-60 nm. The NPs morphology showed a strong absorbance at 374 nm with an estimated gap band of 3.20 eV to 3.32 eV. Microscopy analysis proved the morphology and distribution of the generated nanoparticles to be around 50 nm, with the elemental studies showing the elemental composition of ZnO and further confirming the purity of ZnO NPs. The cytotoxic effect of ZnO NPs was evaluated against wild-type and doxorubicin-resistant MCF-7 and MDA-MB-231 breast cancer cell lines. The results showed the ability of ZnO NPs to inhibit the prefoliation of MCF-7 and MDA-MB-231 prefoliation through the induction of apoptosis without significant differences in both wild-type and resistance to doxorubicin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Molecules (Basel, Switzerland) - 27(2022), 6 vom: 11. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aljabali, Alaa A A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-cancer therapy |
|---|
| Anmerkungen: |
Date Completed 30.03.2022 Date Revised 01.04.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/molecules27061827 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33865433X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33865433X | ||
| 003 | DE-627 | ||
| 005 | 20231226001146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/molecules27061827 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM33865433X | ||
| 035 | |a (NLM)35335190 | ||
| 035 | |a (PII)1827 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aljabali, Alaa A A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis, Characterization, and Assessment of Anti-Cancer Potential of ZnO Nanoparticles in an In Vitro Model of Breast Cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.03.2022 | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Advanced innovations for combating variants of aggressive breast cancer and overcoming drug resistance are desired. In cancer treatment, ZnO nanoparticles (NPs) have the capacity to specifically and compellingly activate apoptosis of cancer cells. There is also a pressing need to develop innovative anti-cancer therapeutics, and recent research suggests that ZnO nanoparticles hold great potential. Here, the in vitro chemical effectiveness of ZnO NPs has been tested. Zinc oxide (ZnO) nanoparticles were synthesized using Citrullus colocynthis (L.) Schrad by green methods approach. The generated ZnO was observed to have a hexagonal wurtzite crystal arrangement. The generated nanomaterials were characterized by transmission electron microscopy (TEM), scanning electron microscopy (SEM), UV-visible spectroscopy. The crystallinity of ZnO was reported to be in the range 50-60 nm. The NPs morphology showed a strong absorbance at 374 nm with an estimated gap band of 3.20 eV to 3.32 eV. Microscopy analysis proved the morphology and distribution of the generated nanoparticles to be around 50 nm, with the elemental studies showing the elemental composition of ZnO and further confirming the purity of ZnO NPs. The cytotoxic effect of ZnO NPs was evaluated against wild-type and doxorubicin-resistant MCF-7 and MDA-MB-231 breast cancer cell lines. The results showed the ability of ZnO NPs to inhibit the prefoliation of MCF-7 and MDA-MB-231 prefoliation through the induction of apoptosis without significant differences in both wild-type and resistance to doxorubicin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-cancer therapy | |
| 650 | 4 | |a green synthesis | |
| 650 | 4 | |a nanomedicine | |
| 650 | 4 | |a triple negative | |
| 650 | 4 | |a zinc oxide nanoparticles | |
| 650 | 7 | |a Plant Extracts |2 NLM | |
| 650 | 7 | |a Zinc Oxide |2 NLM | |
| 650 | 7 | |a SOI2LOH54Z |2 NLM | |
| 700 | 1 | |a Obeid, Mohammad A |e verfasserin |4 aut | |
| 700 | 1 | |a Bakshi, Hamid A |e verfasserin |4 aut | |
| 700 | 1 | |a Alshaer, Walhan |e verfasserin |4 aut | |
| 700 | 1 | |a Ennab, Raed M |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Trad, Bahaa |e verfasserin |4 aut | |
| 700 | 1 | |a Al Khateeb, Wesam |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Batayneh, Khalid M |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Kadash, Abdulfattah |e verfasserin |4 aut | |
| 700 | 1 | |a Alsotari, Shrouq |e verfasserin |4 aut | |
| 700 | 1 | |a Nsairat, Hamdi |e verfasserin |4 aut | |
| 700 | 1 | |a Tambuwala, Murtaza M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 27(2022), 6 vom: 11. März |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:6 |g day:11 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules27061827 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 6 |b 11 |c 03 | ||